Loading...
XNAS
TMDX
Market cap4.70bUSD
Jun 06, Last price  
139.05USD
1D
2.55%
1Q
106.12%
IPO
460.69%
Name

Transmedics Group Inc

Chart & Performance

D1W1MN
P/E
132.66
P/S
10.65
EPS
1.05
Div Yield, %
Shrs. gr., 5y
19.91%
Rev. gr., 5y
79.64%
Revenues
442m
+82.74%
6,209,0007,685,00013,017,00023,604,00025,639,00030,262,00093,459,000241,623,000441,540,000
Net income
35m
P
-24,065,000-20,823,000-23,756,000-33,547,000-28,748,000-44,215,000-36,231,000-25,028,00035,464,000
CFO
49m
P
-24,109,000-23,098,000-25,984,000-32,286,000-30,265,000-28,864,000-45,817,000-13,028,00048,803,000
Earnings
Jul 29, 2025

Profile

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
IPO date
May 02, 2019
Employees
212
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
441,540
82.74%
241,623
158.53%
93,459
208.83%
Cost of revenue
404,044
243,138
124,896
Unusual Expense (Income)
NOPBT
37,496
(1,515)
(31,437)
NOPBT Margin
8.49%
Operating Taxes
316
(1,643)
66
Tax Rate
0.84%
NOPAT
37,180
128
(31,503)
Net income
35,464
-241.70%
(25,028)
-30.92%
(36,231)
-18.06%
Dividends
Dividend yield
Proceeds from repurchase of equity
955
145,977
BB yield
-0.04%
-8.00%
Debt
Debt current
2,727
4,070
1,444
Long-term debt
465,164
523,653
74,970
Deferred revenue
Other long-term liabilities
59,372
Net debt
131,241
132,911
(125,268)
Cash flow
Cash from operating activities
48,803
(13,028)
(45,817)
CAPEX
(151,847)
(11,907)
Cash from investing activities
(129,303)
(193,953)
54,513
Cash from financing activities
22,874
400,418
167,927
FCF
(113,186)
(192,089)
(66,048)
Balance
Cash
336,650
394,812
201,182
Long term investments
500
Excess cash
314,573
382,731
197,009
Stockholders' equity
228,603
137,202
187,375
Invested Capital
518,287
517,981
67,555
ROIC
7.18%
0.04%
ROCE
5.02%
EV
Common stock shares outstanding
35,217
32,517
29,557
Price
62.35
-21.01%
78.93
27.88%
61.72
222.13%
Market cap
2,195,770
-14.45%
2,566,596
40.69%
1,824,235
244.76%
EV
2,327,011
2,699,507
1,698,967
EBITDA
37,496
6,662
(27,959)
EV/EBITDA
62.06
405.21
Interest
14,409
10,791
3,726
Interest/NOPBT
38.43%